drugset
drugset / Trial / NCT07147257

A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions

NCT07147257 ↗

Phase 1 Completed 238 enrolled Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindOther

Summary

A Single-Center, Randomized, Single-Blind, Single-Dose, Parallel-Group Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants under Fasting Conditions

Timeline

Start
2025-02-12
Primary completion
2025-05-06
Completion
2025-05-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject CHS-1420 Unknown 40 mg Subcutaneous

Indications

No indication recorded.